Lancet Regional Health-Europe最新文献

{"title":"Migration control enters the clinic: a public health red line.","authors":"The Lancet Regional Health-Europe","doi":"10.1016/j.lanepe.2026.101703","DOIUrl":"https://doi.org/10.1016/j.lanepe.2026.101703","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"64 ","pages":"101703"},"PeriodicalIF":13.0,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13147805/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147846017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-amyloid therapies and the transformation of Alzheimer's care pathways: early lessons from the frontline","authors":"Massimo Filippi ,&nbsp;Giordano Cecchetti ,&nbsp;Edoardo G. Spinelli ,&nbsp;Alma Ghirelli ,&nbsp;Giulia Rugarli ,&nbsp;Stefano Pisano ,&nbsp;Elisa Canu ,&nbsp;Federica Agosta","doi":"10.1016/j.lanepe.2026.101609","DOIUrl":"10.1016/j.lanepe.2026.101609","url":null,"abstract":"<div><div>The introduction of anti-amyloid monoclonal antibodies marks a major shift in Alzheimer's disease (AD) care, moving treatment toward biological modification and reshaping diagnostic and organizational models. At the Center for Alzheimer's and Related Diseases (CARD), IRCCS San Raffaele Hospital (Milan, Italy), among the first European tertiary centers to initiate both lecanemab and donanemab, we developed a structured fast-track pathway to support timely and safe access to therapy. Our early real-world experience highlights three critical domains. First, patient selection requires integration of cognitive, functional, and biological data, moving beyond rigid global score thresholds. Second, safety monitoring must balance ARIA risk with real-world feasibility through risk-adapted MRI surveillance. Third, effective implementation depends on transparent communication and continuous shared decision-making, particularly when benefit is uncertain or safety events occur. These elements underscore that the impact of disease-modifying therapies will depend not only on pharmacology, but on coordinated care models supported by real-world registries.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"64 ","pages":"Article 101609"},"PeriodicalIF":13.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146162013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex–specific associations between frailty and long-term outcomes in patients with acute myocardial infarction: a national population-based study","authors":"Hasan Mohiaddin ,&nbsp;Chijioke Horatio Mosanya ,&nbsp;Claire Lawson ,&nbsp;Kamlesh Khunti ,&nbsp;Angela Wood ,&nbsp;Iain B. Squire ,&nbsp;Gerry P. McCann ,&nbsp;Abdulla A. Damluji ,&nbsp;Sergio Buccheri ,&nbsp;Mohamad A. Alkhouli ,&nbsp;Mamas A. Mamas ,&nbsp;Muhammad Rashid","doi":"10.1016/j.lanepe.2026.101612","DOIUrl":"10.1016/j.lanepe.2026.101612","url":null,"abstract":"<div><h3>Background</h3><div>Frailty and female sex are both recognised independent predictors of adverse outcomes after acute myocardial infarction (AMI). While females presenting with AMI are known to have a higher burden of frailty than males, it is unknown whether this fully explains sex-based disparities in outcomes, or if the prognostic impact of frailty itself differs between the sexes.</div></div><div><h3>Methods</h3><div>We conducted a retrospective national cohort study using data from the Myocardial Ischaemia National Audit Project (MINAP), linked to hospital admission and mortality registries in England and Wales between 2005 and 2019. Frailty was assessed using the Secondary Care Administrative Records Frailty (SCARF) index and categorised as fit, mild, moderate, or severe. Multivariable Cox proportional hazards models were used with a primary outcome of all-cause mortality at 1-year.</div></div><div><h3>Findings</h3><div>Of 931,133 patients with AMI, 317,967 (34.1%) were female. Frailty was more prevalent in females than in males (severe frailty: 53,065 [16.7%] vs. 64,018 [10.4%]). Males received more intensive therapeutic care across all frailty levels. After multivariable adjustment, the relationship between severe frailty and 1-year all-cause mortality was 26% greater in males than in females (relative hazard ratio [rHR]: 1.26, 95% CI 1.19–1.32, P-interaction &lt;0.001). This corresponded to an adjusted absolute risk difference of 1.19% (95% CI 0.58%–1.79%)</div></div><div><h3>Interpretation</h3><div>In this national AMI cohort, while frailty was more prevalent in females, its association with 1-year mortality was significantly greater in males. This sex-specific effect of frailty challenges current risk-assessment paradigms and underscores the need for sex-informed care pathways.</div></div><div><h3>Funding</h3><div><span>National Institute for Health and Care Research</span> and <span>British Heart Foundation Centre of Research Excellence</span>, Leicester.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"64 ","pages":"Article 101612"},"PeriodicalIF":13.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146161966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing oncology innovation under persistent constraints.","authors":"Dario Trapani, Giuseppe Curigliano","doi":"10.1016/j.lanepe.2026.101694","DOIUrl":"https://doi.org/10.1016/j.lanepe.2026.101694","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"64 ","pages":"101694"},"PeriodicalIF":13.0,"publicationDate":"2026-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13147806/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147846012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjunctive betamethasone treatment of hypoxaemic adults hospitalised with <i>Mycoplasma pneumoniae</i> community-acquired pneumonia: an open-label, multicentre, randomised, controlled trial.","authors":"Karl Hagman, Magnus Hedenstierna, Elina Andersson Norlén, Karin Biasoletto, Maria Eklund Josephson, Carl-Johan Fraenkel, Elin Hedman, Johan Ljungberg, Oskar Ljungquist, Viktor Månsson, David Nygren, Milena de Oliveira E Costa, Cecilia Rydén, Jørgen Skov Jensen, Göran Stenlund, Jonas Tverring, Lisa Wasserstrom, Anna C Nilsson, Johan Ursing","doi":"10.1016/j.lanepe.2026.101610","DOIUrl":"https://doi.org/10.1016/j.lanepe.2026.101610","url":null,"abstract":"<p><strong>Background: </strong>Adjunctive corticosteroid therapy appears to be beneficial for adults with severe community-acquired pneumonia (CAP), but data on <i>Mycoplasma pneumoniae</i> CAP are limited. This study aimed to evaluate if adjunctive betamethasone reduced time to resolution of hypoxaemia in adults hospitalised with <i>M. pneumoniae</i> CAP.</p><p><strong>Methods: </strong>An open-label, multicentre, randomised, controlled trial was conducted at eight Swedish hospitals. Adults admitted with <i>M. pneumoniae</i> CAP and hypoxaemia (SpO₂ <93% and respiratory rate >20 breaths/min) were eligible. Exclusion criteria included asthma and diabetes mellitus. Participants were randomised (1:1) to either standard care without corticosteroids or adjunctive oral betamethasone (3 mg daily on days 1-2, and 2 mg daily on days 3-5). Antibiotic treatment was standardised to 200 mg doxycycline once daily for 10 days. The primary outcome was time to resolution of hypoxaemia in an intention-to-treat analysis. Safety was assessed in participants receiving at least one betamethasone dose. The study was registered with the EU Clinical Trials Register (EudraCT 2016-002585-32) and is completed.</p><p><strong>Findings: </strong>Between March 1, 2018, and November 14, 2024, 70 participants were enrolled: 36 in the betamethasone group and 34 in the control group. The median age was 42 years (IQR 28-49) including 40 (57%) male and 30 (43%) female participants. All participants achieved resolution of hypoxaemia except two who withdrew consent. Time to resolution of hypoxaemia was shorter in the betamethasone group (HR 1.82 [95% CI 1.10-3.02], p = 0.020) compared to the standard of care group, with an estimated median of 2.3 (95% CI 1.8-2.7) and 3.6 (95% CI 1.9-5.3) days, respectively. Adverse events were similar between study groups. Severe adverse events were rare, and none were attributed to betamethasone treatment.</p><p><strong>Interpretation: </strong>Adjunctive betamethasone was well tolerated and significantly shortened the duration of hypoxaemia in adults hospitalised with <i>M. pneumoniae</i> CAP in this open-label trial.</p><p><strong>Funding: </strong>The Swedish Society of Medicine.</p>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"64 ","pages":"101610"},"PeriodicalIF":13.0,"publicationDate":"2026-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13147758/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147845987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corticosteroids for <i>Mycoplasma pneumoniae</i> community-acquired pneumonia: promising evidence from a randomised controlled trial.","authors":"Bijan Teja, John C Marshall","doi":"10.1016/j.lanepe.2026.101677","DOIUrl":"https://doi.org/10.1016/j.lanepe.2026.101677","url":null,"abstract":"","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"64 ","pages":"101677"},"PeriodicalIF":13.0,"publicationDate":"2026-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13147765/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147846001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lung aeration and gas exchange in preterm infants developing moderate-to-severe bronchopulmonary dysplasia: a multicentre prospective study from the PATH-BPD cohort","authors":"Daniele De Luca ,&nbsp;Luca Bonadies ,&nbsp;Costanza Neri ,&nbsp;Barbara Loi ,&nbsp;Teresa Maria Silva-Garcia ,&nbsp;Guillermo Ramos Noguera ,&nbsp;Laura Vivalda ,&nbsp;Giulia Res ,&nbsp;Maria de las Nieves Cidoncha-Fuertes ,&nbsp;Carlos Baena-Palomino ,&nbsp;Lorenzo Zanetto ,&nbsp;Luca Vedovelli ,&nbsp;Dario Gregori ,&nbsp;Eugenio Baraldi ,&nbsp;Almudena Alonso-Ojembarrena","doi":"10.1016/j.lanepe.2025.101584","DOIUrl":"10.1016/j.lanepe.2025.101584","url":null,"abstract":"<div><h3>Background</h3><div>We lack data about the early evolution of lung pathophysiology in infants developing moderate-to-severe broncho-pulmonary dysplasia (msBPD). We aimed to describe lung aeration and gas exchange during the early phase of msBPD development and identify the critical moments at which they change.</div></div><div><h3>Methods</h3><div>Prospective, multicentre, cohort study performed in three European centres enrolling preterm (≤30 weeks’ gestation) infants evaluated at 10, 21, 28 days (D) of life and 34 and 36 weeks (W) post-menstrual age, while receiving as little invasive ventilation as possible. Lung aeration was assessed with quantitative lung ultrasound. Pulse oximetry and transcutaneous blood gas measurements were used to calculate the SpO₂/FiO₂ and PtcO₂/FiO₂ ratios. msBPD was defined using NIH-2001, NICHD-2018 and Jensen definitions.</div></div><div><h3>Findings</h3><div>347 infants were studied, of which 80, 79 and 89 had msBPD, using the three definitions, respectively. Lung aeration and oxygenation were always poorer, since D10, in patients with msBPD than in those without it. The difference in lung aeration (β ranging from +0.009 (95% CI: 0; 0.01) to +0.012 (95% CI: 0.01; 0.02), depending on the used definition, <em>p</em> &lt; 0.001) and carbon dioxide (β ranging from +0.01 (95% CI: 0; 0.02) to +0.014 (95% CI: 0.01; 0.02), depending on the used definition, <em>p</em> &lt; 0.001) between patients with and without msBPD increased overtime. Results were similar regardless of the BPD definition. The strongest discrimination was obtained by the lung aeration evolution (β(t) = 0.227 (95% CI: 0.152, 0.302), <em>p</em> &lt; 0.001) with a peak at 26 days.</div></div><div><h3>Interpretation</h3><div>Patients who develop msBPD consistently demonstrate early and typical pathophysiological phenotypes regardless of the BPD definition. These data highlight critical moments in the development of msBPD and are not captured by currently available BPD definitions.</div></div><div><h3>Funding</h3><div>Only institutional funding to support the author's working time was used.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"63 ","pages":"Article 101584"},"PeriodicalIF":13.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145927917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"European Code Against Cancer 5th edition: 14 ways you can help prevent cancer","authors":"Carolina Espina ,&nbsp;David Ritchie ,&nbsp;Elio Riboli ,&nbsp;Hans Kromhout ,&nbsp;Silvia Franceschi ,&nbsp;Iris Lansdorp-Vogelaar ,&nbsp;Theresa M. Marteau ,&nbsp;Ioanna Bakogianni ,&nbsp;Nadia Vilahur ,&nbsp;Catherina J. Alberts ,&nbsp;Urska Ivanus ,&nbsp;Ariadna Feliu ,&nbsp;Erica D'Souza ,&nbsp;Hajo Zeeb ,&nbsp;Giota Mitrou ,&nbsp;Tit Albreht ,&nbsp;Joakim Dillner ,&nbsp;Jérôme Foucaud ,&nbsp;Marta Manczuk ,&nbsp;Jose María Martin-Moreno ,&nbsp;Joachim Schüz","doi":"10.1016/j.lanepe.2026.101592","DOIUrl":"10.1016/j.lanepe.2026.101592","url":null,"abstract":"<div><div>Despite the growing cancer burden in the European Union, public awareness of effective prevention is low. In response, Europe's Beating Cancer Plan has supported the development of the 5th edition of the European Code Against Cancer (ECAC5). Using a transparent, stepwise decision-making process, around 80 experts reviewed the latest scientific evidence on cancer prevention and used modern communication strategies to update the previous edition. An innovation in ECAC5 is the inclusion of population-level recommendations, aiming to structurally influence the systems that shape individual choices and improve environmental conditions to which all citizens are involuntarily exposed. ECAC5 includes 14 actionable, evidence-based recommendations for individuals to reduce their cancer risk alongside their respective policy recommendations. All are presented through equity lens, with attention to co-benefits for preventing other non-communicable diseases and tailoring messages to diverse audiences. Clear evidence-based statements on cancer risks factors and effective preventive interventions will empower citizens to make healthier choices, call policymakers to act, foster public support for effective policies, and contribute to more effective cancer prevention.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"63 ","pages":"Article 101592"},"PeriodicalIF":13.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146023193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short-term effects of cannabis legalisation in Germany on driving under the influence of cannabis: a difference-in-differences analysis using Austria as a control","authors":"Anna Schranz ,&nbsp;Anja Knoche-Becker ,&nbsp;Moritz Rosenkranz ,&nbsp;Uwe Verthein ,&nbsp;Jakob Manthey","doi":"10.1016/j.lanepe.2026.101593","DOIUrl":"10.1016/j.lanepe.2026.101593","url":null,"abstract":"<div><h3>Background</h3><div>In April 2024, Germany legalised adult cannabis possession and cultivation, and in August 2024 established legal THC-limits for driving. This study aimed to examine short-term impacts on (1) cannabis use and (2) driving under the influence of cannabis (DUIC), and (3) investigates the extent of DUIC involving cannabis combined with alcohol or other drugs (DUIC(+)).</div></div><div><h3>Methods</h3><div>Data came from two cross-sectional population surveys in Germany and Austria (control) before (t₀: Nov–Dec 2023) and after legalisation (t₁: Nov 2024–Jan 2025). We assessed 12-month cannabis use among adults aged 18–64 (Germany: n_t0 = 6670, n_t1 = 9692; Austria: n_t0 = 2132, n_t1 = 2102) and DUIC among at least monthly cannabis users (excluding medical use; Germany: n_t0 = 393, n_t1 = 589; Austria: n_t0 = 86, n_t1 = 92) using a difference-in-differences (DiD) approach. For t₁, we compared the proportion of DUIC(+) and cannabis-only DUIC(−) episodes among all DUIC episodes by use frequency.</div></div><div><h3>Findings</h3><div>In Germany, cannabis use rose from 12·1% to 14·4%, but this trend did not significantly differ from Austria (DiD-effect: <em>OR</em> = 1·18, 95% CI 0·95–1·48, <em>p</em> = 0·141, weighted). Among at least monthly users, DUIC decreased slightly from 28·5% to 26·8% (unweighted), with no significant difference compared with Austria (DiD-effect: <em>aOR</em> = 0·68, 95% <em>CI</em> 0·27–1·68, <em>p</em> = 0·408). Results held across sensitivity analyses including additional confounders and negative controls. At t₁, DUIC(+) accounted for 21·5% of episodes. DUIC(−) was most common among daily users, DUIC(+) among weekly users.</div></div><div><h3>Interpretation</h3><div>Eight months after legalisation, no significant short-term effects on cannabis use or DUIC were observed. DUIC(+), associated with higher traffic risk, was most common among weekly users. A comprehensive evaluation of the cannabis reform requires further monitoring of DUIC and traffic data.</div></div><div><h3>Funding</h3><div><span>Federal Highway</span> and <span>Transport Research Institute</span> (FE 82.0816/2023).</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"63 ","pages":"Article 101593"},"PeriodicalIF":13.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146023191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stigma from healthcare professionals and care-limiting behaviors in individuals with substance use disorders: a mixed-methods study","authors":"Mathias Luderer ,&nbsp;Dorothea Stockreiter ,&nbsp;Annette Binder ,&nbsp;Laura Müller ,&nbsp;Franca Burger ,&nbsp;Nathalie Stüben ,&nbsp;Andreas Reif","doi":"10.1016/j.lanepe.2025.101587","DOIUrl":"10.1016/j.lanepe.2025.101587","url":null,"abstract":"<div><h3>Background</h3><div>Stigmatization of individuals with substance use disorders (SUDs) by healthcare professionals (HCPs) is a recognized problem, but its direct impact on patient treatment choices has not been systematically quantified. We aimed to provide first robust, quantitative metrics of non-disclosure, treatment avoidance, and treatment discontinuation for any medical treatment directly attributable to HCP stigma and to explore the lived experiences underpinning these behaviors.</div></div><div><h3>Methods</h3><div>We conducted a prospective mixed-methods study with 119 adult inpatients with SUDs at a German university hospital (2021–2024). A self-developed questionnaire assessed stigma-related behaviors and their association with self-stigmatization. Qualitative data were analyzed using reflexive thematic analysis (RTA). A person with lived experiences contributed to writing up the manuscript.</div></div><div><h3>Findings</h3><div>49.6% (95% CI 40.3–58.9; n = 59/119) reported non-disclosure of substance use, 36.1% (95% CI 27.5–45.5; n = 43/119) avoided necessary medical treatment, and 29.4% (95% CI 21.4–38.5; n = 35/119) discontinued treatment due to stigma. Internalized stigma significantly predicted all three outcomes (aORs 1.055–1.075, p ≤ .001). RTA identified “Institutional Stigma” (addiction as a “moral failing”), “Barriers to Care” (obstacles to respectful treatment), and “Cost of Disclosure” (negative consequences such as hostility after revealing substance use).</div></div><div><h3>Interpretation</h3><div>Stigma from HCPs is a quantifiable contributor of treatment disengagement, representing a direct threat to patient safety and a major contributor to the SUD treatment gap. These findings underscore the urgent need for evidence-based interventions, including training HCPs across all specialties in non-stigmatizing communication, to improve healthcare engagement for this vulnerable population and narrow the substantial treatment gap.</div></div><div><h3>Funding</h3><div>None.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"63 ","pages":"Article 101587"},"PeriodicalIF":13.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145978785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}